Dr. David Shlaes

The $2 Billion Bomb: Rewards for New Antibiotics

It's indisputable that we need to develop new antibiotics – and fast. It's also all-but-indisputable that once this gets into the hands of politicians, they will screw it up. They sure did this time. American Council advisor Dr. David Shlaes explains.

Antibiotics: Some Welcome Movement at the FDA

Dr. David Shlaes, American Council advisor and infectious disease expert, has been blogging about antibiotics since 2009. His latest entry concerning the FDA is rather encouraging, but it's also a bit disturbing.

Antibiotics hit the news big time. But is it in time?

We at ACSH have been writing about the dire situation we face because of antibiotic resistance for years. Both Dr. Josh Bloom and ACSH advisor Dr. David Shlaes a world renowned expert in the field have written many times about the looming antibiotic crisis, a time when common infections that were previously treatable are no longer so

The FDA may be doing something productive to combat antibiotic resistance

The federal government took another small step in the battle to combat antibiotic-resistant bacteria. In the same week the WHO released a statement on the growing global crisis of antibiotic

The growing antibiotic crisis: Much talk, little action

The World Health Organization just issued a statement warning us that the world is failing miserably to adequately fight antibiotic resistance. Although the group does a very fine job in pointing out the consequences of this impending catastrophe, it fails to offer much in the way of a solution.

Europe is ahead of the US in the antibiotics game, says Dr. Shlaes

We have often written about the antibiotic crisis in which we now find ourselves. The main problem standing in the way of progress in the development of new, effective antibiotics seems to be that it s very expensive, and companies are not incentivized to invest time and money in this area. A blockbuster drug (e.g. Lipitor) has to

Are hepatitis C drugs too expensive?

As we discussed here two months ago, Gilead s Sovaldi a revolutionary treatment that can actually cure hepatitis C was under attack for its cost ($1000 per daily pill for 12 weeks, or $84,000).